Demuth Tim's Form 4 filing
Palvella Therapeutics, Inc. (PVLA) · filed May 16, 2022
- Accession no.
- 0001583648-22-000030
- Filed
- May 16, 2022
- Trade date
- May 13, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $10.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Demuth TimCIK 0001875267 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2022 | Common Stock | PPurchaseAcquired | +6,000 | $1.71F1 | +$10,260 | 6,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Purchase price was 1.65 Euros per share which was converted into dollars using the noon buying rate of 1.00 Euro to $1.03745 based on information provided on May 13, 2022 via Xignite.
Referenced by the price of 1 transaction in Table I.